CALML3-AS1: A Potential Drug Target and Biomarker (G100132159)

Target Name: CALML3-AS1

NCBI ID: G100132159

CALML3-AS1

Other Name(s): CALML3 antisense RNA 1 | CALML3-AS1 variant 1 | CALML3 antisense RNA 1, transcript variant 1

CALML3-AS1: A Potential Drug Target and Biomarker

Calbindin-like protein 3 (CALML3) is a member of the actinin family, which is characterized by the presence of a characteristic domain called the calbindin-like protein 3 (CALML3) gene. This gene has been identified as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. In this article, we will discuss the biology of CALML3, its potential as a drug target, and its potential as a biomarker for various diseases.

The Biology of CALML3

CALML3 is a 21-kDa protein that is expressed in various tissues, including muscle, pancreas, and brain. It is composed of a N-terminus of 124 amino acids, a catalytic domain of 18 amino acids, and a C-terminus of 84 amino acids. The catalytic domain of CALML3 contains a single protein kinase domain (pK) that is responsible for the protein's catalytic activity.

Expression and Localization of CALML3

CALML3 is expressed in various tissues and cells throughout the body, including muscle fibers, nerve fibers, pancreatic beta cells, and brain cortical regions. It is predominantly expressed in the brain, where it is found in the endoplasmic reticulum (ER) and in the cytoplasm. In addition to its expression in the brain, CALML3 is also expressed in other tissues, including muscle, pancreas, and blood vessels.

CALML3's localization to the ER and cytoplasm suggests that it is involved in the intracellular signaling pathway. It has been shown to play a role in several intracellular signaling pathways, including the TGF-β pathway, the Wnt pathway, and the Hedgehog pathway. In addition, studies have shown that CALML3 can interact with several protein partners, including the transcription factor, NF-kappa-B, and the protein kinase, p300.

Potential Drug Targets

CALML3 has been identified as a potential drug target due to its unique biology and the involvement of several intracellular signaling pathways. One of the potential drug targets for CALML3 is the TGF-β pathway, which is involved in cell growth, differentiation, and repair. It is thought that the TGF-β pathway may be involved in the regulation of CALML3's intracellular signaling, and that inhibition of this pathway could be a potential therapeutic approach for various diseases.

Another potential drug target for CALML3 is the Wnt pathway, which is involved in cell-cell signaling and tissue development. It is thought that the Wnt pathway may be involved in the regulation of CALML3's intracellular signaling and that inhibition of this pathway could be a potential therapeutic approach for various diseases.

CALML3 has also been shown to play a role in the Hedgehog pathway, which is involved in cell-cell signaling and tissue patterning. It is thought that the Hedgehog pathway may be involved in the regulation of CALML3's intracellular signaling and that inhibition of this pathway could be a potential therapeutic approach for various diseases.

Potential Biomarkers

CALML3 has been shown to have several potential biomarkers. One of the most promising biomarkers for CALML3 is its ability to bind to several protein partners, including the transcription factor, NF-kappa-B, and the protein kinase, p300. This suggests that CALML3 may be involved in the regulation of intracellular signaling pathways and that its levels may be relevant as biomarkers for various diseases.

Another potential biomarker for

Protein Name: CALML3 Antisense RNA 1

The "CALML3-AS1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CALML3-AS1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets